Ozmosi | RPH-001 Drug Profile

Product Description

Bevacizumab Biosimilar

Mechanisms of Action: VEGF Inhibitor

Novel Mechanism: No

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Company: TRPHARM
Company Location: Europe
Company Founding Year: 2013
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Colorectal Cancer|Liver Cancer

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success	Latest Trial Update Date	Data Updated
NCT05238831	STUDY00020679	P1	Withdrawn	Sarcoma\|Soft Tissue Cancer\|Pancreatic Cancer\|Prostate Cancer\|Ovarian Cancer\|Breast Cancer	2026-05-31	4%	2024-11-27	Primary Endpoints\|Treatments
NCT03878524	PRIME	P1	Terminated	Myeloproliferative Disorders\|Acute Myelomonocytic Leukemia\|Blast Crisis\|Lymphocytic Chronic B-Cell Leukemia\|Preleukemia\|Chronic Myelomonocytic Leukemia\|Anemia, Refractory\|Precursor Cell Lymphoblastic Leukemia-Lymphoma\|Chronic Myeloid Leukemia\|Prostate Cancer\|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma\|Chronic, Atypical, BCR-ABL Negative Myeloid Leukemia\|Myelofibrosis\|Adenocarcinoma\|Thrombocytosis\|Pancreatic Cancer\|Breast Diseases\|Myelogenous, Chronic, BCR-ABL Positive Leukemia\|Acute Lymphoid Leukemia\|Juvenile Myelomonocytic Leukemia,\|Myeloid, Accelerated Leukemia\|Myelodysplastic Syndrome\|Acute Myeloid Leukemia\|Lymphoma, Non-Hodgkin\|Leukemia, Plasma Cell\|Chronic Lymphoid Leukemia\|Lymphoma, B-Cell\|Myelodysplastic-Myeloproliferative Diseases\|Acute Monocytic Leukemia\|Multiple Myeloma\|Breast Cancer	2020-12-10		2024-11-27	Primary Endpoints\|Treatments
NCT03659305	СL01011063	P1	Completed	Oncology Unspecified\|Healthy Volunteers	2019-01-26	64%	2019-03-22	Primary Completion Date\|Study Completion Date\|Treatments\|Trial Status
NCT03131700	RPH001BEV01	P1	Withdrawn	Healthy Volunteers	2018-01-01		2019-03-21	Treatments
2017-001634-26	2017-001634-26	P1	Unknown status	Non-Small-Cell Lung Cancer	2017-05-29		2025-06-20	Primary Completion Date\|Start Date\|Study Completion Date\|Treatments\|Trial Status
NCT07288034	IMMUNO-BIOMAP	P2	Not yet recruiting	Non-Small-Cell Lung Cancer	2028-09-22		2025-12-18	Primary Endpoints\|Treatments
NCT05001880	NCI-2021-08573	P2	Recruiting	Mesothelioma	2026-08-20		2025-10-10	Primary Completion Date\|Primary Endpoints\|Study Completion Date
NCT02364713	MC1365	P2	Terminated	Peritoneal Cancer\|Clear Cell Adenocarcinoma\|Ovarian Cancer\|Carcinosarcoma\|Endometrioid Carcinoma\|Mucinous Adenocarcinoma\|Transitional Cell Carcinoma\|Clear Cell Sarcoma	2022-01-13		2025-08-27	Patient Enrollment\|Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments\|Trial Status
NCT05863195	The PUMP Trial	P3	Recruiting	Liver Cancer\|Colorectal Cancer	2029-06-30		2024-11-27	Primary Endpoints\|Treatments

Recent News Events

Date	Type	Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

RPH-001

Alternative Names: rph-001, rph001, rph 001 Clinical Status: Inactive Latest Update: 2026-02-25 Latest Update Note: Clinical Trial Update